Because Google controls over 70% of online searches, it is an incredible resource for analyzing online search behavior. Recently, the search term “Cord Blood” became one of the 20 most expensive keywords on Google Adwords, an incredible finding given the variety and total volume of searches that occur through Google.
In recent groundbreaking research, Dr. William H. Frey II (Director, Alzheimer’s Research Center) and Dr. Lusine Danielyan announced that they have discovered and patented that therapeutic cells, including adult stem cells, can be delivered to the brain using a noninvasive intranasal delivery method.
This non-invasive intranasal method for bypassing the blood-brain barrier can rapidly delivery and target therapeutic agents to the brain along the olfactory and trigeminal neural pathways while reducing systemic exposure and side effects. The intranasal insulin treatment discovered by Dr. Frey for Alzheimer’s disease has been shown in multiple clinical trials to improve memory in both Alzheimer’s patients and normal adults.
The cord blood banking industry is a rapidly evolving industry. Every month there are major events occurring in the sector that shift industry dynamics. Often, these events are announcements of technical or scientific advancements. Sometimes they are announcements of major industry alliances. Occasionally, they are announcements of a new industry competitor, a major milestone, or a significant funding award.
For those of us interested in the cord blood industry, tracking these shifting industry dynamics is of paramount importance. For this reason, this post covers the most significant cord blood industry news events as of February 2015.
The cord blood banking industry has grown increasingly complex over the past few years. While rates of growth within the industry were robust during the early 2000’s, it is no longer the rapid growth market that it used to be. There is now increased market competition, tighter regulatory standards, more substantial government oversight, and increased public scrutiny given toward cord blood industry practices.
This was a major year for stem cells, as we saw the first ever induced pluripotent stem cell (iPSC) trial in humans, as well as several large mergers and acquisitions within the stem cell industry. One of the most prominent was the buyout of Life Technologies by industry behemoth Thermo Fisher Scientific.
There were also major technical advances that occurred, including notable advances made by scientists at the Harvard Stem Cell Institute (HSCI) toward the creation of human insulin-producing cells from human embryonic stem cells, as well as advances in the bio-fabrication of human tissues using 3-D cell printing technology, led by Guohao Dai of the Rensselaer Polytechnic Institute, among others.